# The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression

> **NCT06708156** · PHASE3 · RECRUITING · sponsor: **Oupushifang Pharmaceutical Technology Co., Ltd.** · enrollment: 606 (estimated)

## Conditions studied

- Myopia
- Myopia Progression

## Interventions

- **DRUG:** Atropine sulfate eye drops 0.01%
- **DRUG:** Atropine sulfate eye drops 0.02%
- **DRUG:** Placebo eye drops

## Key facts

- **NCT ID:** NCT06708156
- **Lead sponsor:** Oupushifang Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-15
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 606 (ESTIMATED)
- **Last updated:** 2024-12-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06708156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06708156, "The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06708156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*